April 20, 2024

Pa­tients tak­ing Take­da’s En­tyvio for Crohn’s dis­ease will now have the op­tion of a sub­cu­ta­neous ver­sion. Take­da an­nounced the la­bel ex­pan­sion on Fri­day, sev­er­al months

CSL Vi­for is look­ing to close out a Eu­ro­pean an­ti-com­pet­i­tive in­ves­ti­ga­tion with a pro­posed mar­ket­ing cam­paign. The Eu­ro­pean Com­mis­sion be­gan in­ves­ti­gat­ing Vi­for Phar­ma, now CSL

No­vo Nordisk de­cid­ed to dis­con­tin­ue its long-act­ing in­sulin Lev­emir last No­vem­ber, and three De­moc­rats in the Sen­ate want to know why, lay­ing out their ques­tions

FDA Com­mis­sion­er Robert Califf told law­mak­ers he’s ready to work with them to bring more drug man­u­fac­tur­ing to the US and laid out the agency’s

Plus, news about TScan Ther­a­peu­tics: His­to­gen files for Chap­ter 11 bank­rupt­cy: The biotech, which stopped work in Sep­tem­ber, filed a pe­ti­tion with the US Bank­rupt­cy Court for

Will Ver­tex’s “pipeline-in-a-prod­uct” pay off? That’s the bet be­hind the com­pa­ny’s $4.9 bil­lion ac­qui­si­tion of Alpine Im­mune Sci­ences and its mid-stage IgA nephropa­thy drug, which

An acute com­pe­ti­tion is emerg­ing among drug de­vel­op­ers look­ing at a rare neu­ro­log­i­cal dis­or­der known as chron­ic in­flam­ma­to­ry de­myeli­nat­ing polyneu­ropa­thy, or CIDP, and Wall Street

Roche’s Genen­tech said that Ale­cen­sa scored a la­bel ex­pan­sion from the FDA, with the drug now ap­proved as an ad­ju­vant treat­ment fol­low­ing tu­mor re­sec­tion in

Re­cur­sion Phar­ma­ceu­ti­cals has poached Na­jat Khan from John­son & John­son, where she led AI ef­forts at one of health­care’s gi­ants. Khan will serve as chief